We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Depomed Completes Enrollment for Non-Hormonal Treatment Study in Menopausal Hot Flashes
News

Depomed Completes Enrollment for Non-Hormonal Treatment Study in Menopausal Hot Flashes

Depomed Completes Enrollment for Non-Hormonal Treatment Study in Menopausal Hot Flashes
News

Depomed Completes Enrollment for Non-Hormonal Treatment Study in Menopausal Hot Flashes

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Depomed Completes Enrollment for Non-Hormonal Treatment Study in Menopausal Hot Flashes"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Depomed, Inc. has announced that it has completed enrollment of Breeze 1, the first of two pivotal Phase 3 clinical trials in Depomed's registration program of DM-5689 for the non-hormonal treatment of menopausal hot flashes.

“We are glad that we achieved this milestone today and look forward to the results of both Breeze 1 and Breeze 2 trials in hot flashes expected later this year. We are well on plan in this important execution year for us,” said Carl A. Pelzel, president and chief executive officer of Depomed.

“DM-5689 has the potential to become a significant alternative treatment of hot flashes for the large number of menopausal women in this country. I am glad that we have achieved this milestone in our clinical study today and I would like to convey my thanks to all the Breeze 1 investigators who have made this possible. We look forward to seeing the results later this year,” added Dr. Risa Kagan, of East Bay Physicians Medical Group and Clinical Professor, Dept. Ob/Gyn, UCSF, the lead investigator for the Breeze 1 study.
Advertisement